Japan, China And Korea To Work Together Towards Clinic Trials Data Sharing
This article was originally published in PharmAsia News
Drug regulatory directors from Japan, China and Korea held a joint meeting in Tokyo April 14 to promote sharing clinical trial data among the three countries. Japan's Pharmaceutics and Food Safety Bureau Chief and directorial officers from the Korean FDA and China's State FDA agreed to exchange information and to conduct a joint research project on the difference in ethnicities, the biggest barrier to sharing clinical trials data. The three countries also set up a working group to promote joint research projects. (Click here for more - Japanese language
You may also be interested in...
Insider Analysis From Fountain Medical Development: Clinical Development in China - Current Status And Future Trends
By Joanne Jiang, Ph.D, Fountain Medical Development Ltd
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.